Search for Terms or Answers
There were new developments in the treatment of axial Spondyloarthritis (AS) at ACR 2019. The first area is on the use of anti-IL17A drugs, secukinumab and ixekizumab in non-radiographic AS. The second area is the use of JAK-1 inhibitor Upadacitinib in radiographic AS.
Dr. Jack Cush presents his favorite abstracts and presentations from Rheumatology Round Up and ACR 2019.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews recent journal articles and info bits from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
Dr. Jack Cush delivers select commentary on select news and journal articles from the past week on RheumNow.com.
Even though oral bisphosphonates are widely used, there is an inordinate concern over the risk of osteonecrosis of the jaw (ONJ). A new UK study suggests that the risk of ONJ is elevated six fold by the use of biphosphonates.
Dr. Jack Cush reviews the News and Journal Reports from this week on RheumNow.com.
JAMA Internal Medicine has an analysis of the growing trend of more women enrolling in medical schools in the last few decades, such that more than half of US Med school matriculants in 2017 were women. Also in 2017, 42% of residents in internal medicine were women. The reported analy
Dr. Jack Cush reviews the news and articles from the past week on RheumNow.com.
As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.
Rheumatology leaders commend CMS for proposing E/M code changes and urge agency to make additional changes to final rule.d
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.
Pregnancy for patients with lupus has long been considered high risk and associated with both medical and obstetric complications, but outcomes have improved over the last 2 decades and continue to improve.
The highlight of the last day of #ACR19 is the Rheumatology Roundup Highlights #ACRBest by Drs. John Cush @RheumNow and Arthur Kavanaugh @ACRheum always worth attending with great take home messages #rheum https://t.co/eMdvc2byKG
RheumNow Podcast is up! When youre hot youre hot! Watch it on youtube>> https://t.co/GlqMzjUnhE or listen to the podcast in your car on iTues, Apple podcast or on Stitcher or SoundCloud>> https://t.co/a1zE7VXtog
90 SLE pts (SLEDAI<6) on immunosuppressives were given PBO or Live Virus zostavax - Vax pts had significantly higher Wk 6 anti-VZV IgG, more injection site reactions (31 vs 7%). 3 pts flared (1PBO; 2 Zostavax) and no one developed zoster postvaccination https://t.co/pVrQ4tHAwY
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
